Literature DB >> 27940335

Comparison Between the Kansas City Cardiomyopathy Questionnaire and New York Heart Association in Assessing Functional Capacity and Clinical Outcomes.

Nael Hawwa1, Amanda R Vest2, Rahul Kumar3, Rony Lahoud1, James B Young1, Yuping Wu4, Eiran Z Gorodeski1, Leslie Cho5.   

Abstract

OBJECTIVE: The Kansas City Cardiomyopathy Questionnaire (KCCQ) has emerged as a patient-centered heart failure-specific health status measure. It currently lacks routine and widespread use in clinical practice and trials. The purpose of this study was to examine the correlation between KCCQ and cardiopulmonary exercise testing (CPET) parameters and clinical outcomes, compared with the New York Heart Association functional classification (NYHA). METHODS AND
RESULTS: We performed a single-centered observational analysis of 432 patients who presented to the Heart Failure Department, completed the KCCQ, and underwent CPET. The 1-year clinical outcome assessed was a composite of mortality, heart failure hospitalization, and need for heart transplantation or left ventricular assist device. In the KCCQ, the physical limitation domain had a correlation with peak VO2 similar to NYHA (r = 0.48; P < .001; and r = -0.48; P < .001; respectively), and slightly better correlation with ventilatory threshold (r = 0.42; P < .001; and r = -0.40; P < .001; respectively). According to model validation, the KCCQ physical limitation domain and NYHA were similar predictors of peak VO2 (r2 = 0.229; and r2 = 0.227; respectively). KCCQ predicted the specified 1-year clinical outcome (hazard ratio 0.75, 95% confidence interval 0.69-0.82; P < .001) and provided incremental predictive ability when added to a model that included NYHA, with a net reclassification index of 76.1% (P < .001).
CONCLUSIONS: KCCQ and NYHA provide similar assessment of functional capacity. KCCQ predicts 1-year clinical outcomes, providing incremental value over NYHA. These findings support its routine use in clinical care, as well as its potential to serve as a measure in clinical trials.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heart failure; KCCQ; NYHA; functional capacity; peak VO(2)

Mesh:

Year:  2016        PMID: 27940335     DOI: 10.1016/j.cardfail.2016.12.002

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  9 in total

Review 1.  Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations.

Authors:  Alexandra Arvanitaki; Eleni Michou; Andreas Kalogeropoulos; Haralambos Karvounis; George Giannakoulas
Journal:  ESC Heart Fail       Date:  2020-05-05

2.  Validation of heart failure quality of life tool and usage to predict all-cause mortality in acute heart failure in Uganda: the Mbarara heart failure registry (MAHFER).

Authors:  Samson Okello; Fardous Charles Abeya; Boniface Amanee Elias Lumori; Suzan Joan Akello; Christopher Charles Moore; Brian H Annex; Andrew J Buda
Journal:  BMC Cardiovasc Disord       Date:  2018-12-12       Impact factor: 2.298

3.  Impact of cardiac resynchronisation therapy on burden of hospitalisations and survival: a retrospective observational study in the Northern Region of New Zealand.

Authors:  Khang-Li Looi; Nigel Lever; Andrew Gavin; Robert Doughty
Journal:  BMJ Open       Date:  2019-05-27       Impact factor: 2.692

4.  Screening and Initiating Supportive Care in Patients With Heart Failure.

Authors:  Quynh Nguyen; Kaiming Wang; Anish Nikhanj; Dale Chen-Song; Ingrid DeKock; Justin Ezekowitz; Mehrnoush Mirhosseini; Bibiana Cujec; Gavin Y Oudit
Journal:  Front Cardiovasc Med       Date:  2019-10-22

5.  Patients report more severe daily limitations than recognized by their physicians.

Authors:  Renata R T Castro; Emer Joyce; Neal K Lakdawala; Garrick Stewart; Anju Nohria; Michael M Givertz; Akshay Desai; Eldrin F Lewis; Lynne W Stevenson
Journal:  Clin Cardiol       Date:  2019-09-30       Impact factor: 2.882

Review 6.  How to develop a national heart failure clinics network: a consensus document of the Hellenic Heart Failure Association.

Authors: 
Journal:  ESC Heart Fail       Date:  2020-02-26

7.  How Symptomatic Should a Hypertrophic Obstructive Cardiomyopathy Patient Be to Consider Alcohol Septal Ablation?

Authors:  Brandon M Jones; Amar Krishnaswamy; Nicholas G Smedira; Milind Y Desai; E Murat Tuzcu; Samir R Kapadia
Journal:  J Am Heart Assoc       Date:  2017-05-16       Impact factor: 5.501

8.  Change of Health-Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure.

Authors:  Nariman Sepehrvand; Anamaria Savu; John A Spertus; Jason R B Dyck; Todd Anderson; Jonathan Howlett; Ian Paterson; Gavin Y Oudit; Padma Kaul; Finlay A McAlister; Justin A Ezekowitz
Journal:  J Am Heart Assoc       Date:  2020-08-19       Impact factor: 5.501

9.  Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire.

Authors:  Razvan Capota; Sebastian Militaru; Alin Alexandru Ionescu; Monica Rosca; Cristian Baicus; Bogdan Alexandru Popescu; Ruxandra Jurcut
Journal:  Health Qual Life Outcomes       Date:  2020-10-30       Impact factor: 3.186

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.